Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
240.74
+0.75 (0.31%)
Aug 7, 2025, 4:00 PM - Market closed
0.31%
Market Cap9.32B
Revenue (ttm)1.28B
Net Income (ttm)147.70M
Shares Out 38.73M
EPS (ttm)3.74
PE Ratio64.39
Forward PE56.14
Dividendn/a
Ex-Dividend Daten/a
Volume203,030
Open241.36
Previous Close239.99
Day's Range237.27 - 242.13
52-Week Range163.63 - 310.00
Beta0.40
AnalystsStrong Buy
Price Target300.47 (+24.81%)
Earnings DateJul 29, 2025

About DESP

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW... [Read more]

Sector Healthcare
IPO Date Sep 18, 2015
Employees 4,500
Stock Exchange NYSE
Ticker Symbol PEN
Full Company Profile

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for PEN stock is "Strong Buy." The 12-month stock price target is $300.47, which is an increase of 24.81% from the latest price.

Price Target
$300.47
(24.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

Other symbols: ACLXBSXEWEXASGHISRGLLY
7 hours ago - Seeking Alpha

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tu...

8 days ago - PRNewsWire

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Adam Elsesser - Co-Founder, Chairman, President & CEO Cecilia Furlong - Corporate Participant ...

9 days ago - Seeking Alpha

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.

9 days ago - PRNewsWire

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

Other symbols: ABBVABTALNYAZNEWLLYMRK
15 days ago - Reuters

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

ALAMEDA, Calif. , July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market clos...

5 weeks ago - PRNewsWire

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy,...

6 weeks ago - Seeking Alpha

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatm...

7 weeks ago - PRNewsWire

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

ALAMEDA, Calif. , June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and so...

2 months ago - PRNewsWire

Penumbra, Inc. to Present at Upcoming Investor Conferences

ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times ...

2 months ago - PRNewsWire

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesd...

3 months ago - PRNewsWire

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

3 months ago - Seeking Alpha

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.

3 months ago - Benzinga

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO ...

3 months ago - Seeking Alpha

Penumbra, Inc. Reports First Quarter 2025 Financial Results

ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.

3 months ago - PRNewsWire

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market clos...

4 months ago - PRNewsWire

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

ALAMEDA, Calif. , April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data pre...

4 months ago - PRNewsWire

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has noti...

5 months ago - PRNewsWire

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

Penumbra Inc PEN is trading higher after the company reported better-than-expected fourth-quarter earnings.

6 months ago - Benzinga

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - ...

6 months ago - Seeking Alpha

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decemb...

6 months ago - PRNewsWire

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 af...

7 months ago - PRNewsWire

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P.

7 months ago - PRNewsWire

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst

Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction.

8 months ago - Benzinga

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on We...

9 months ago - PRNewsWire